Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
76-90 of 4547 results
Jazz Pharmaceuticals, ImmunoGen to collaborate on hematology-related ADC products
By PBR Staff Writer
Ireland-based Jazz Pharmaceuticals has partnered with ImmunoGen to develop and commercialize the US biotechnology company’s two early-stage, hematology-related antibody-drug conjugate (ADC) products.
Drug Research > Drug Discovery & Development > News
CSL Behring to buy US biotechnology firm Calimmune
By PBR Staff Writer
CSL Behring, the US subsidiary of Australia-based CSL has agreed to acquire Calimmune, an American biotechnology company focused on developing ex vivo hematopoietic stem cell (HSC) gene therapy.
Drug Research > Drug Discovery & Development > News
Regenxbio to buy US firm Dimension Therapeutics
By PBR Staff Writer
Gene therapy firm Regenxbio has signed an agreement to acquire US-based firm Dimension Therapeutics.
Drug Research > Drug Discovery & Development > News
Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody
Ligand Pharmaceuticals will get a payment of $2m from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other selected territories.
Drug Research > Drug Discovery & Development > News
Samsung Bioepis, Takeda to co-develop multiple novel biologic therapies
Samsung Bioepis has signed collaboration agreement with Takeda Pharmaceutical to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas.
Drug Research > Drug Discovery & Development > News
Atreca raises $35m to advance novel cancer immunotherapies
Atreca, a privately held biotechnology company developing novel therapeutics drawn from human immune responses, has closed its Series B round of financing with an investment totaling $35m.
Drug Research > Drug Discovery & Development > News
GSK to evaluate Insilico’s AI technology to enhance drug discovery process.
By PBR Staff Writer
GlaxoSmithKline and Insilico Medicine are partnering to assess how the latter’s artificial intelligence (AI) technology can help in the drug discovery process.
Drug Research > Drug Discovery & Development > News
Evotec completes Aptuit acquisition
German company Evotec has completed the acquisition of US-based Aptuit.
Drug Research > Drug Discovery & Development > News
Vicarius Pharma secures $21.8m financing
Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.
Drug Research > Drug Discovery & Development > News
Oxford BioMedica announces collaboration for gene and cell therapy manufacturing
A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing.
Drug Research > Drug Discovery & Development > News
Apellis Pharmaceuticals raises $60m in new funding round
Apellis Pharmaceuticals has completed a $60m Series E preferred stock financing led by Sectoral Asset Management.
Drug Research > Drug Discovery & Development > News
Oxford BioMedica secures commercial supply licence from UK MHRA
Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material for commercial supply.
Drug Research > Drug Discovery & Development > News
Researchers develop new drug that could treat and limit Parkinson’s disease
Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.
Drug Research > Drug Discovery & Development > News
Bristol-Myers Squibb to acquire IFM Therapeutics to expand cancer pipeline
By PBR Staff Writer
Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.
Drug Research > Drug Discovery & Development > News
Evotec to acquire Aptuit for $300m
German small molecule drugs developer Evotec has agreed to acquire pharmaceutical services company Aptuit for $300m from private equity firm Welsh, Carson, Anderson & Stowe (WCAS).
Drug Research > Drug Discovery & Development > News
76-90 of 4547 results